TAE Life Sciences has announced that its board of directors has appointed Rob Hill as its new Chief Executive Officer (CEO). Hill, who had been COO, succeeds Bruce Bauer, who served as CEO since the company was founded in 2017. Image courtesy: TAE Life Sciences.
July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed Rob Hill as its new Chief Executive Officer (CEO). Hill joined TAE Life Sciences as Chief Operating Officer (COO) in October 2018. The company is a pre-clinical stage biotech company focused on advancing the field of radiation oncology through accelerator-based Boron Neutron Capture Therapy (BNCT), based in Santa Monica, CA.
Effective immediately, Hill succeeds Bruce Bauer, who served as CEO since the company was founded in 2017. According to the company statement, Bauer is stepping aside for medical reasons, but will remain active on the board of directors as chairman emeritus.
The board of directors praised Bauer’s work, noting the following achievements under his leadership: TAE Life Sciences licensed its accelerator technology from TAE Technologies, the world's largest and most advanced private fusion energy company; secured Series A and Series B funding; developed and deployed its first neutron beam system; arranged strategic partnerships with world-renowned cancer centers for clinical trials; and envisioned and established a world-class pharmaceutical development team.
The company announcement noted that Hill brings invaluable expertise to his new role as CEO of TAE Life Sciences, with an impressive track record in the radiation oncology industry and extensive experience in corporate strategy, product development, and global market expansion. It added that Hill’s deep understanding of the industry, coupled with his visionary leadership, will play a pivotal role in propelling the company forward as it enters the critical clinical trial phase for its groundbreaking Alphabeam BNCT system with its novel targeted boron drugs.
Under Hill’s leadership as COO, TAE successfully delivered its neutron beam system and accelerator to its joint-venture partner in China, overcoming many challenges posed by the global pandemic. Hill has already made significant contributions to the company's growth and success, and played a crucial role in securing partnerships with prominent medical institutions and medical distribution partners from around the world, growing the company’s R&D organization, and fundraising for the company, according to the announcement.
"I am truly honored to lead TAE Life Sciences, a company poised to revolutionize cancer treatment and save countless lives,” said Hill. He added, “I’m confident that our Alphabeam BNCT machine, combined with our proprietary targeted drugs, will profoundly impact the lives of patients worldwide. With our exceptional team, we'll bring this groundbreaking therapy to market, and make a meaningful difference in the fight against cancer."
Before joining TAE Life Sciences, Hill held various senior executive positions at Accuray Incorporated, a renowned provider of radiation oncology solutions. During his tenure, he led the development and launch of innovative products, drove strategic partnerships, and played a crucial role in transforming the company's product development organization. His accomplishments at Accuray include launching new radiation therapy products, intellectual property development, and driving significant revenue growth.
More information: www.taelifesciences.com
September 17, 2026 
